মূল্য
দামগুলো আনুমানিক MRP এবং ফার্মেসিভেদে ভিন্ন হতে পারে। সর্বশেষ নথিভুক্ত দামের সাথে তুলনা করে ট্রেন্ড দেখানো হয়।
সব দামের পরিবর্তন →ইঙ্গিত ও ব্যবহার
Reucent XR এর জন্য নির্দেশিত:
ডোজ নির্দেশিকা
শুধুমাত্র নির্দেশিকা তথ্য
প্রদর্শিত ডোজগুলি সরকারি উৎসের সাধারণ নির্দেশিকা। ব্যক্তিগতকৃত ডোজের জন্য সর্বদা আপনার ডাক্তার বা ফার্মাসিস্টের পরামর্শ নিন।
প্রাপ্তবয়স্ক:
Rheumatoid Arthritis: 15 mg once daily. Psoriatic Arthritis: Adults 18 Years of Age and Older: 15 mg once daily. Atopic Dermatitis: 12 kg-65 kg (Weighing at least 40 kg): Initiate with 15 mg once daily. If an adequate response is not achieved, consider increasing the dosage to 30 mg once daily. Discontinue if an adequate response is not achieved with the 30 mg dose. Adults 65 Years of Age and Older: 15 mg once daily. Ulcerative Colitis (Adult Patients): Induction: 45 mg once daily for 8 weeks. Maintenance: 15 mg once daily. A dosage of 30 mg once daily may be considered for patients with refractory, severe or extensive disease. Discontinue if an adequate therapeutic response is not achieved with the 30 mg dosage. Crohn's Disease (Adult Patients) Induction: 45 mg once daily for 12 weeks. Maintenance: 15 mg once daily. A dosage of 30 mg once daily may be considered for patients with refractory, severe or extensive disease. Discontinue if an adequate therapeutic response is not achieved with the 30 mg dosage. Ankylosing Spondylitis: 15 mg once daily. Non-radiographic Axial Spondyloarthritis: 15 mg once daily. Polyarticular Juvenile Idiopathic Arthritis: (30 kg and greater): 15 mg once daily.
পার্শ্বপ্রতিক্রিয়া
Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and nonradiographic axial spondyloarthritis: Adverse reactions (≥ 1%) were: upper respiratory tract infections, herpes zoster, herpes simplex, bronchitis, nausea, cough, pyrexia, acne, and headache.Atopic Dermatitis: Adverse reactions ( ≥1%) are: upper respiratory tract infections, acne, herpes simplex, headache, blood creatine phosphokinase increased, cough, hypersensitivity, folliculitis, nausea, abdominal pain, pyrexia, increased weight, herpes zoster, influenza, fatigue, neutropenia, myalgia, and influenza like illness.Ulcerative Colitis: Adverse reactions (≥ 5%) reported during induction or maintenance are: upper respiratory tract infections, increased blood creatine phosphokinase, acne, neutropenia, elevated liver enzymes, and rash.Crohn's Disease: Adverse reactions ( ≥5%) reported during induction or maintenance are: upper respiratory tract infections, anemia, pyrexia, acne, herpes zoster, and headache.
সতর্কতা ও নিষেধাজ্ঞা
সতর্কতা ও সাবধানতা
Serious Infections: Avoid use of Upanib in patients with active, serious infection, including localized infections.Malignancy: Consider the risks and benefits of Upanib treatment prior to initiating therapy in patients with a known malignancy.Thrombosis: Consider the risks and benefits prior to treating patients who may be at increased risk of thrombosis. Promptly evaluate patients with symptoms of thrombosis and treat appropriately.Gastrointestinal Perforations: Use with caution in patients who may be at increased risk.Laboratory Monitoring: Recommended due to potential changes in lymphocytes, neutrophils, hemoglobin, liver enzymes and lipids.Embryo-Fetal Toxicity: Upanib may cause fetal harm based on animal studies. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception.Vaccinations: Avoid use of Upanib with live vaccines.